Need Help With This Product?
Our specialists are here to help you find the best product for your application.
iCell Cardiomyocytes², 01434
Products
Kits
- Cryopreserved iCell Cardiomyocytes², 01434
- 30 ml iCell Cardiomyocytes² Plating Medium
- 100 ml iCell Cardiomyocytes² Maintenance Medium
- User’s Guide
genetic status
Quantity (Cells Per Vials)
Catalog #
Catalog #:
Cardiomyocytes² differentiated from human iPS cells, frozen
From
$713.00
Cells Only
- Cryopreserved iCell Cardiomyocytes², 01434
- User’s Guide
genetic status
Quantity (Cells Per Vials)
Catalog #
Catalog #:
Cardiomyocytes² differentiated from human iPS cells, frozen
From
$613.00
Product Overview
iCell® Cardiomyocytes2 are an enhanced version of the extensively validated and predictive iCell Cardiomyocytes product. Derived from induced pluripotent stem cells (iPSCs), iCell Cardiomyocytes2 from FUJIFILM Cellular Dynamics, have been optimized for high-throughput applications.
- Rapid Results iCell Cardiomyocytes2 are optimized for rapid recovery from cryopreservation and are assay-ready as early as 4 days post-thaw. The cells are provided with complete plating and maintenance medium.
- Minimal Handling iCell Cardiomyocytes2 require a limited number of hands-on steps, thereby reducing lab time and potential for contamination.
- Verified Model for Cardiac Safety Assessment iCell Cardiomyocytes2 display intact human cardiac biology with electrophysiological and biochemical responses upon exposure to exogenous agents. The cells are a preferred cellular model for cardiac safety assessment included in the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative.
- Fully Supported Optimized protocols for functional assays, which include multielectrode array (MEA), calcium handling, and impedance, enable robust and reproducible measurements of compound-induced effects on human cardiomyocyte physiology. FCDI’s application scientists provide relevant training and timely assistance to support seamless implementation.
Components:
Our regular business hours are 9:00am to 5:00pm Central Time (USA)
Need Help With This Product?
Our specialists are here to help you find the best product for your application.
Our regular business hours are 9:00am to 5:00pm Central Time (USA)
Technical Docs
PROTOCOLS
Application Protocols
Measuring Cardiac Activity: Functional Maturation on the xCELLigence RTCA ePacer
Application Protocols
Measuring Cardiac Activity: Impedance and Extracellular Field Potential Detection with CardioExcyte 96 System
Application Protocols
Measuring Cardiac Activity: Impedance and Extracellular Field Potential Detection with xCELLigence RTCA CardioECR System
Application Protocols
Measuring Cardiac Activity: Impedance Detection with xCELLigence RTCA Cardio System
Application Protocols
Measuring Cardiac Electrical Activity: Field Potential Detection on the Maestro Multielectrode Array
Application Protocols
Using LEAP to Measure Cardiac Action Potential Morphology
Application Protocols
Measuring Cardiac Activity: Intracellular Calcium Flux Detection with FDSS/µCELL
Application Protocols
Measuring Cardiac Contractility with FLEXcyte 96 System
Application Protocols
Plating iCell Cardiomyocytes2 on CELLvo™ Matrix Plus
Application Protocols
Electrophysiological Recordings of iCell Cardiomyocytes2 on the Patchliner System
Application Protocols
Bioenergetic Analysis of iCell Cardiomyocytes2: Evaluating Mitochondrial function on the XF Pro Analyzer
Application Notes
Structural organization and functional analysis of compound response in 3D human iPSC-derived cardiac tri-culture microtissues
Application Protocols
Contractility Analysis of iCell Cardiomyocytes2: Evaluating iCell Cardiomyocytes2 in co-culture with iCell Cardiac Fibroblasts on the FLEXcyte 96 System
Application Protocols
Generation of 3D iCell CardioSpheres and iCell CardioSpheres² with iCell Products
Application Notes
A robust and reproducible QPatch® II assay for Nav1.5 measurements
Application Protocols
Using Liposome-mediated Transfection for Gene Delivery
USER DOCS
Quick Guide
iCell CardioTox Assay Medium Quick Guide
Quick Guide
iCell Cardiomyocytes2, 01434 Quick Guide
User's Guides
iCell Cardiomyocytes2
Datasheet
iCell Cardiomyocytes2
Biosafety Document
iCell Cardiomyocytes and iCell Cardiomyocytes2 01434 Biosafety Document
Safety Data Sheet
iCell Cell-Based Products Safety Data Sheet - Asia
Safety Data Sheet
iCell Cell-Based Products Safety Data Sheet
Safety Data Sheet
iCell Cardiomyocytes Maintenance Medium, iCell Cardiomyocytes Plating Medium Safety Data Sheet - Germany
Performance Data
Formation of 3D Cardiac Tri-Culture Microtissues
Three-dimensional multi-cellular systems containing iCell Cardiomyocytes or iCell Cardiomyocytes2, iCell Endothelial Cells and primary cardiac fibroblasts have the potential for greater physiological relevance, predictive power, and mechanistic insight than cardiomyocytes alone. For information on 3D systems, see the Application Protocol: Culturing and Assaying Calcium Transients of 3D Cardiac Tri-Culture Microtissues
Figure 1: Structure of 3D Cardiac Tri-culture Microtissues Over Time.
Microtissues were formed containing 5,000 or 10,000 total cells in S-bio 96-well plates. Compact, contracting microtissues were obtained by Day 4. (A) Panel of phase contrast 10X images of 5,000 cell tri-culture spheroids over time using the Incucyte S3. (B) Quantification of 5,000 cell tri-culture microtissue diameter. Each dot represents a microtissue. Mean and SEM are indicated. (C) Comparison of Day 14 microtissue diameter of 5,000 cell tri-culture microtissues with 10,000 cell tri-culture microtissues. Each dot represents a microtissue. Mean and SEM are indicated. (D) H&E staining of Day 14, 3D cardiac tri-culture microtissue formed with 10,000 total cells. Staining shows the absence of a necrotic core.
Figure 2: 3D Cardiac Tri-culture Microtissues Response to Beta Adrenergic Agonist Isoproterenol
(A) Chronotropic response: Control iCell Cardiomyocytes, 11713 only microtissues (CM) and tri-culture microtissues exhibit an increase in beat rate with increasing concentrations of isoproterenol. (B) Inotropic response: Control iCell Cardiomyocytes, 11713 only microtissues (CM) do not increase amplitude with increasing concentrations of isoproterenol. Tri-culture microtissues demonstrate a twofold increase in beat amplitude with increasing concentrations of isoproterenol.
Enhanced Inotropic Response when Plated in Tri-Culture
3D cardiac tri-culture microtissues containing iCell Cardiomyocytes or iCell Cardiomyocytes2, iCell Endothelial Cells and cardiac fibroblasts demonstrated a positive response to the inotropic compound isoproterenol, which is characteristic of mature cardiomyocytes. For information on 3D triculture systems, see the Application Protocol: Culturing and Assaying Calcium Transients of 3D Cardiac Tri-Culture Microtissues
Compatible with High-Sensitivity Detection of Calcium Transients in Tri-Culture
Three-dimensional multi-cellular systems containing iCell Cardiomyocytes or iCell Cardiomyocytes2, iCell Endothelial Cells and cardiac fibroblasts demonstrate enhanced amplitude in calcium transient assays. For information on 3D systems, see the Application Protocol: Culturing and Assaying Calcium Transients of 3D Cardiac Tri-Culture Microtissues
Figure 3: Baseline Calcium Transients in Cardiomyocyte and Tri-culture Microtissues at Day 14
Calcium transients were measured using EarlyTox calcium dye. (A) Representative calcium traces for 5,000 and 10,000 total cell 3D Tri-culture cardiac microtissues. (B) Beat rate is not different between 5,000 or 10,000 cell triculture microtissues and control cardiomyocyte only microtissues. (C) Representative calcium traces for 5,000 cell tri-culture and 5,000 cell cardiomyocytes only microtissues (CM only). (D) Amplitude is significantly higher in triculture microtissue compared to cardiomyocyte only microtissues (CM only) at 5,000 cells, but similar at 10,000 cells
Figure 4: iCell Cardiomyocytes2 Capture Phenotypic Responses across Different Classes of Cardioactive Compounds
iCell Cardiomyocytes2 Capture Phenotypic Responses across Different Classes of Cardioactive Compounds
iCell Cardiomyocytes2 Provide an Accurate System for Detecting Ion Channel Block
Panels A and B show the expected increase in the field potential duration blocking IKr with E-4031. Panels C and D show the expected decrease in the field potential duration blocking the L-type calcium channels with NI. iCell Cardiomyocytes2 were exposed to the indicated compounds at the concentrations listed and the effects quantified ± SEM.
Figure 5: iCell Cardiomyocytes2 Provide an Accurate System for Detecting Ion Channel Block
Product Highlights
A Multitude of Applications
iCell Cardiomyocytes2 have demonstrated utility for electrophysiological and biochemical assays in toxicology, drug discovery, and basic life science research applications. Contact our Technical Support team for information on using iCell Cardiomyocytes2 in these types of studies.
- Multielectrode array (MEA) recordings
- Impedance-based measurements
- Calcium flux assays with the FDSS/µCELL Functional Drug Screening System
- Liposome-mediated transfection
Publications
A Targeted Metabolomics-Based Assay Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Identifies Structural and Functional Cardiotoxicity Potential Palmer JA, Smith AM, Gryshkova V, Donley ELR, Valentin JP, Burrier RE (2020) Toxicol Sci.174(2):218-240. (2020)
Engineered Cardiac Tissues Generated in the Biowire II: A Platform for Human-Based Drug Discovery Nicole T Feric, Isabella Pallotta, Rishabh Singh, Danielle R Bogdanowicz, Marietta M Gustilo, Khuram W Chaudhary, Robert N Willette, Tim P Chendrimada, Xiaoping Xu, Michael P Graziano, Roozbeh Aschar-Sobbi (2019) Toxicol Sci. 172(1):89-97. (2019)
Assessment of Proarrhythmic Potential of Drugs in Optogenetically Paced Induced Pluripotent Stem Cell-derived Cardiomyocytes Patel D., Stohlman J., Dang Q., Strauss D.G., and Blinova K. (2019) Toxicol. Sci. 170(1):167-179 . (2019)
A Platform for Generation of Chamber-Specific Cardiac Tissues and Disease Modeling Zhao Y, Rafatian N, Feric NT, Cox BJ, Aschar-Sobbi R, Wang EY, Aggarwal P, Zhang B, Conant G, Ronaldson-Bouchard K, Pahnke A, Protze S, Lee JH, Huyer LD, Jekic D, Wickeler A, Naguib HE, Keller GM, Vunjak-Novakovic G, Broeckel U, Backx PH, Radisic M (2019) Cell 76(4):913-927. (2019)
International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment Blinova K, Dang Q, Millard D, Smith G, Pierson J, Guo L, Brock M, Lu HR, Kraushaar U, Zeng H, Shi H, Zhang X, Sawada K, Osada T, Kanda Y, Sekino Y, Pang L, Feaster TK, Ralf R, Stockbridge N, Strauss DG, Gintant G (2018) Cell Rep. 24(13):3582-3592. (2018)
Deconvoluting Kinase Inhibitor Induced Cardiotoxicity Lamore SD, Ahlberg E, Boyer S, Lamb ML, Hortigon-Vinagre MP, Rodriguez V, Smith GL, Sagemark J, Carlsson L, Bates SM, Choy AL, Stålring J, Scott CW, Peters MF (2017) Toxicol Sci. doi: 10.1093/toxsci/kfx082. (2017)
A New Paradigm for Drug-induced Torsadogenic Risk Assessment using Human iPS cell-derived Cardiomyocytes Blinova K, Stohlman J, Vicente J, Chan D, Johannesen L, Hortigon-Vinagre MP, Zamora V, Smith G, Crumb WJ, Pang L, Lyn-Cook B, Ross J, Brock M, Chvatal S, Millard D, Galeotti L, Stockbridge N, Strauss DG.(2017) Toxicol Sci. 155(1):234-247 (2017)